Navigation Links
Knowing doctor's financial interests doesn't deter clinical trial participants
Date:4/2/2008

DURHAM, N.C. -- A patient's willingness to participate in a clinical trial may be unaffected by the disclosure of a researcher's financial interests in the study, unless the amount of money a researcher stands to earn depends on the results of the trial, according to a new study by researchers at the Duke Clinical Research Institute (DCRI), Wake Forest University, and the Johns Hopkins Berman Institute of Bioethics.

We found that the patients we surveyed rated most types of financial disclosures less important in influencing their decisions to participate than other factors, like the risks and benefits of the proposed treatment, said Kevin Weinfurt, Ph.D., deputy director of the DCRIs Center for Clinical and Genetic Economics, and lead investigator on the study. We also found that some patients are savvy enough to distinguish between different types of financial relationships, and they have different reactions based on these distinctions.

The researchers published their findings in the April 2, 2008 online edition of the Journal of General Internal Medicine. The study was funded by the National Heart, Lung and Blood Institute.

More than 3,600 diabetes and asthma patients were surveyed for this study, and the researchers asked each to answer questions related to their willingness to participate in a hypothetical clinical trial. Each electronic survey contained one of five financial disclosure statements.

The disclosure statements ranged from the generic -- the doctor running the trial might benefit financially from the study -- to the more specific -- dealing with per capita payments, and ownership of equity on the part of the researcher or the institution, Weinfurt said. We found that none of the disclosures significantly affected subjects willingness to participate with the exception of ownership of equity on the part of the researcher.

This disclosure stated that the study leader could gain or lose money depending
'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Veterinary Pet Insurance Data Reveals Well-Intended Pet Owners Unknowingly Poisoning Their Pets
2. Knowing Your Risks Can Stop the Sneak Thief of Sight
3. Knowing Heart Risk Keeps Patients on Cholesterol Drugs
4. Majority of U.S. Doctors Back National Insurance Plan
5. TriWest Recognizes Contributions of TRICARE Docs to Military Community on Doctors Day
6. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
7. Doctors See How Cancer Drug Can Damage Kidneys
8. 3 new honorary doctors at Karolinska Institutet
9. Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS 08
10. Drugs, Doctors and Death: Heath Ledger Becomes Another Victim
11. Doctors should watch for depression in arthritis patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...S, N.J., Nov. 21 Today, ...l intervention in treating 88 percent of patients ...mericans treated for a chronic condition account f...d 75 percent of all medical costs. A proprietary ...edco Health Solutions, Inc. (NYSE: MHS ) signifi...
(Date:11/21/2008)... popular drugs do not cause genetic damage that ca...ealthDay News) -- Two popular medications for trea...D) do not cause genetic damage linked to an increa..., The study, done by researchers at Duke Univer... Health, counters a previous one that reported bio...
(Date:11/21/2008)..., a new and deadly diseaseits cause remains a myst...was teeming with citizens, soldiers and refugees o...s streets filled with corpses, social order broke ...ned twice and Athens lost a third of its populatio...d the beginning of the end of the Golden Age of Gr...
(Date:11/21/2008).... 21 /PRNewswire/ -- For the second year in a r...Cann Healthcare Worldwide,s agency network won mor... the 22nd annual international RX Club Show. , ...ices won a total of 59 RX Club Awards of Excellenc...Cann Healthcare Worldwide agencies include Caudex ...
Breaking Medicine News(10 mins):Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4
...anderbilt University Medical Center reveal a surpr...rt that the Golgi apparatus -- a stack of pancake... out to their cellular destinations -- is the sour...icroscopic fibers. Scientists have long thought t...
...sorder figures among seem to soar out of proportio...published in response to parliamentary questions ... children being hospitalized with eating disorders...cade. This mainly comprises of people under the ag...
... and women seeking surgical procedures among most ...oration procedures were performed worldwide in 200...cs released today from a recent member survey cond...ation Surgery (ISHRS) -- the world's leading medic...
...rnment took a step Wednesday toward offering vacci... as 12, a measure that could be carried out by la...and Immunisation (JCVI) recommended the use of vac... (HPV), a sexually transmitted infection which cau...
Other Medicine News:Health News:Research in the Origin of Microtubules 2Health News:Research in the Origin of Microtubules 3Health News:Eating Disorder Figures Among Children Soars 2Health News:Hair Restoration Procedures Performed Worldwide Increased 34 Percent in 2006 2Health News:Hair Restoration Procedures Performed Worldwide Increased 34 Percent in 2006 3Health News:Girls Could Be Vaccinated Against Cervical Cancer in Britain 2
(Date:11/20/2008)...ewswire/ -- Milk. It does a body good. And,now it...fter years of,research, scientists at OncoNutriti...lk that stimulate the body,s own production of ant...s Release, go to:, http://www.prnewswire.com/mnr/e...ew cancer therapies, the chief scientist, Dr. Davi...
(Date:11/20/2008)...-- Clinical data from a prospective,registry pres... shows DVT,treatment with the Trellis(R) Peripher...anta Clara, CA) successfully breaks up the blood c... This technique, called isolated pharmacomechanic... and safely than current catheter-directed thrombo...
(Date:11/19/2008)... Amgen,(Nasdaq: AMGN )...bsidiary of,Takeda Pharmaceutical Company Limited...the Phase 3 MONET1 trial evaluating motesanib (AMG...tin for the first-line treatment of,advanced non-...y suspended,following a planned safety data revie...
(Date:11/19/2008)...re/ -- Isogen, a contract development and,manufac...ounced the first,phase launch of its contract fac...ally address the process, facility and capacity pr...ghly-niched, low-volume clinical and,early-stage ... Companies can invest over $100 million and four ...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2BioMarin Announces First Quarter 2008 Financial Results 4955 1BioMarin Announces First Quarter 2008 Financial Results 4955 2BioMarin Announces First Quarter 2008 Financial Results 4955 3BioMarin Announces First Quarter 2008 Financial Results 4955 4BioMarin Announces First Quarter 2008 Financial Results 4955 5BioMarin Announces First Quarter 2008 Financial Results 4955 6BioMarin Announces First Quarter 2008 Financial Results 4955 7BioMarin Announces First Quarter 2008 Financial Results 4955 8BioMarin Announces First Quarter 2008 Financial Results 4955 9BioMarin Announces First Quarter 2008 Financial Results 4955 10BioMarin Announces First Quarter 2008 Financial Results 4955 11Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 1Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 2Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 3Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 4Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 1Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 2Engineers harness cell phone technology for use in medical imaging 4950 1Engineers harness cell phone technology for use in medical imaging 4950 2Engineers harness cell phone technology for use in medical imaging 4950 3Engineers harness cell phone technology for use in medical imaging 4950 4
... THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 30, 2...esults from a pivotal Phase 3,trial which showed t...clonal antibody directed against the epidermal gro...free survival (PFS) compared,to best supportive ca...who had failed fluoropyrimidine, irinotecan, and,o...
... ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A ... before last winter may have been,less effective t...adults who had flu shots before last winter were o...se who were not vaccinated. The,differences were l...ic.(1) In the winters of 2003/2004 and 2004/2005 a...
Other Medicine Technology:Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 2Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 3Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 4Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 5Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 6Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband.
A rapid rise in intracranial pressure requires early recognition, intervention and continuous monitoring. Ventrix utilizes state-of-the-art fiberoptic technology that gets to the source of pressure.
The Codman ICP Monitoring System provides highly accurate measurements of intracranial pressure at the source-subdural, parenchymal or intraventricular levels. The information is relayed electronical
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)
Medicine Products: